Serum levels of tissue polypeptide antigen (TPA) are related to the proliferative activity and to the mass of the malignancy, differently from any other available tumor marker. We therefore evaluated TPA in comparison with CA15.3 and MCA (mucinous-like carcinoma-associated antigen) in patients with primary breast cancer. TPA was measured in tumor cytosol and in serum. Cytosol and serum TPA levels were not significantly correlated. Serum TPA was higher in patients with locally more advanced disease and in receptor-negative cases. The relation between TPA and disease spread was not directly dependent on tumor bulk, whereas CA15.3 and MCA were highly correlated to the number of positive lymph nodes and tumor size. No correlations were found between TPA and CA15.3 or MCA, and the positivity concordance rate between TPA and CA15.3 or MCA was very low. Patients with higher TPA serum levels showed a worse prognosis in cases with and in those without axillary metastases. From our data we conclude that TPA provides information different from that obtained with breast-specific tumor markers and could therefore be useful in association with CA15.3 and/or MCA In the management of patients with breast cancer.
Get full access to this article
View all access options for this article.
References
1.
BjörklundB.: On the nature and clinical use of tissue polypeptide antigen. Tumor Diagnostik, 1: 9–20, 1980.
2.
BjörklundB., BjörklundV.: Specificity and basis of the tissue polypeptide antigen. Cancer Detect. Prev., 6: 41–50, 1983.
3.
BjörklundB., BjörklundV.: Biochemische und morphologische Grundlagen von TPA: Fortschritte in Richtung auf einen allgemeinen Marker für aktive Tumoren durch monoklonale Kartierung. In: Tumormarkersystem CEA-TPA.LuthgensM., and SchlegelG. (eds.), pp. 14–16, Tumor Diagnostik Verlag, Leonberg, 1987.
4.
BjörklundB., BjörklundV., WiklundB., LundströmR., EkdahlP.H., HagbardL., KaijserK., EklundG., LüningB.: A human tissue polypeptide related to cancer and placenta. I. Preparation and properties. II. Assay technique. III. Clinical studies of 1,483 individuals with cancer and other conditions. In: Immunological Techniques for Detection of Cancer.BjörklundB. (ed.), pp. 133–187, Bonniers, Stockholm, 1973.
5.
BjörklundV., BjörklundB., WittekindC., Von KleistS.: Immunohistochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer. Acta Pathol. Microbiol. Immunol. Scad. Sect. A, 90: 471–476, 1982.
6.
BjörklundB., WiklundB., LüningB., AnderssonK., KallinE., BjörklundV.: Radioimmunoassay of TPA. A laboratory test in cancer. Tumor Diagnostik, 21: 78–84, 1980.
7.
BombardieriE., GionM., MioneR., DittadiR., BruscagninG., BuraggiG.: A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Cancer, 63: 490–495, 1989.
8.
BradfordM.: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dyebinding. Anal. Biochem., 72: 248–253, 1976.
9.
ColomerR., RuibalA., NavarroM., EncaboG., SoleA., SalvadorL.: Circulating CA15/3 levels in breast cancer. Our present experience. Int. J. Biol. Markers, 1: 89–92, 1986.
10.
CoxD.R.: Regression models and life table. J. Roy. Statist. Soc., 34: 187–220, 1972.
11.
E.O.R.T.C. Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16: 1513–1515, 1980.
12.
FisherE.R., RedmondC., FisherB.: Pathologic findings from the National Surgical Adjuvant Breast Project (Prot. N. 4). Discriminants for five-years treatment failure. Cancer, 46(Suppl.): 908–918, 1980.
13.
GionM., MioneR., DittadiR., FasanS., PalliniA., BruscagninG.: Evaluation of CA15.3 serum levels in breast cancer patients. J. Nucl. Med. Allied Sci., 30: 29–36, 1986.
14.
GionM., MioneR., DittadiR., FasanS., PalliniA., BruscagninG.: Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with receptor content in breast carcinoma. Cancer, 57: 917–922, 1986.
15.
KjellgrenK.: The prognostic significance of consecutive determinations of serum tissue polypeptide antigen (TPA) in human breast cancer. In: Carcino Embryonic Proteins.LehmannF.G. (ed.), pp. 607–610, Elsevier/North-Holland Biomedical Press, Amsterdam, 1979.
16.
LüthgensM., LüthgensK., Kruse-JarresJ.D., CaffierH., KrelembergR., SturmG., Schmidt-RhodeP., LenferD.: TPA-IRMA in comparison to TPA-RIA. A multicenter study. Proceedings of the 4th International Conference on Human Tumor Markers, New York, August 26-28, 1987.
17.
LüthgensM., SchlegelG.: CEA+TPA in der Klinischen Tumordiagnostik, insbesondere des Mamma-Karzinoms. Tumor Diagnostik, 2: 63–77, 1980.
18.
MantelN.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163–170, 1966.
19.
MeyerJ.S., RaoB.R., StevensS.C., WhiteW.L.: Low incidence of estrogen receptor in breast carcinoma with rapid rates of cellular replication. Cancer, 40: 2290–2298, 1977.
20.
MrossK., MrossB., WofrumD.I.: Der Wert der TPA Bestimmung bei Malignompatienten. Lab. Med., 7: 231–234, 1983.
21.
NemotoT., CostantineR., ChuT.M.: Human tissue polypeptide antigen in breast cancer. J. Natl. Cancer Inst., 63: 1347–1350, 1979.
22.
NevilleA.M., PatelS., CappM., LaurenceJ.C., CooperE.H., TurbervilleC., CoombesR.C.: The monitoring role of plasma CEA alone and in association with other tumor markers in colorectal and mammary carcinoma. Cancer, 42(Suppl.): 1448–1451, 1978.
23.
OsbornM., WeberK.: Biology of disease. Tumor diagnosis by intermediate filament typing: A novel tool for surgical pathology. Lab. Invest., 48: 372–394, 1983.
24.
Schmidt-RhodeP., SchulzK., SturmG., Raab-FrickA., PrinzH.: CA15.3 as a tumour marker in breast cancer. Int. J. Biol. Markers, 2: 135–142, 1987.
25.
ShekL.L.M., GodolphinW., SpinelliJ.J.: Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients. Br. J. Cancer, 56: 825–829, 1987.
26.
StähliC., CaravattiM., AeschbacherM., KocybaC., TakacsB., CarmannH.: Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes. Cancer Res., 48: 6799–6802, 1988.
27.
StenkvistB., VegeliusJ., Westman-NaeserS., HolmquistJ., NordinB., BengtssonE., EriksonnO.: Analysis of reproducibility of subjective grading system for breast carcinoma. J. Clin. Pathol., 32: 979–985, 1983.
28.
TobiasR., RothwellC., WagnerJ., GreenA., LiuY.-S.K.: Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3. Proc. Symposium American Association for Analytical Clinical Chemistry, Atlanta.
29.
U.I.C.C.: Classification of Malignant Tumours.HermanekP., and SobinL.H. (eds.), Springer-Verlag, Berlin-Heidelberg, 1987.
30.
WalkersT.P., EnterlineJ.P., ShaperJ.H., AbeloffM.O., EttingerD.S.: Biological markers for breast cancer. Cancer, 53: 644–649, 1984.
31.
WeberK., OsbornM., MollR., WiklundB., LüningB.: Tissue polypeptide antigen (TPA) is related to non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a tumor marker. EMBO J., 3: 2707–2714, 1984.
32.
World Health Organization. AzzopardiJ.G., ChepikO.F., HartmannW.H., JafareyN.P., Llombart-BoschA., OzzelloL., RilkeF., SasanoN., SobinL.H.: The WHO histological typing of breast tumors (2nd ed.). Am. J. Clin. Pathol., 78: 806–816, 1982.
